Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1…